文献速递心脏核医学放射性药物与辐射防护

瑞舒伐他汀对HIV感染患者的抗炎作用:一项FDG-PET先导研究

Anti-inflammatory effect of rosuvastatin in patients with HIV infection: An FDG-PET pilot study.
PubMed 文献 · J Nucl Cardiol · 2021-11-24

本研究纳入35例HIV阳性患者,随机分为瑞舒伐他汀10 mg/日治疗组(17例)与常规护理组(18例)治疗6个月,并用18F-FDG PET/CT评估骨髓、脾脏和升主动脉炎症。结果显示,与对照组相比,他汀治疗组骨髓、脾脏和胸主动脉FDG摄取显著下降。

要点

  • HIV阳性患者存在全身炎症标志物升高,包括单核细胞活化标志物。
  • 瑞舒伐他汀10 mg/日治疗6个月可显著降低骨髓、脾脏和胸主动脉FDG摄取。
  • 该研究为先导研究,样本量有限,需进一步验证。

核心结论

  • HIV阳性患者存在显著的全身炎症标志物升高,包括单核细胞活化。
  • 低剂量瑞舒伐他汀治疗可显著降低HIV阳性患者骨髓、脾脏和胸主动脉的FDG摄取。

研究设计与样本

  • 先导研究,35例HIV阳性患者随机分为瑞舒伐他汀10 mg/日组(17例)和常规护理组(18例),治疗6个月。
  • 另选HIV阴性对照队列用于基线血清炎症标志物和单核细胞炎症标志物比较。
  • HIV阳性队列在基线和6个月时进行骨髓、脾脏和胸主动脉的18F-FDG PET/CT显像。

主要发现

  • 与对照组相比,HIV阳性患者CD14++CD16-和CCR2表达降低,血清IL-7、IL-8和MCP-1水平升高。
  • 他汀治疗组较对照组骨髓FDG摄取变化为-10.3 ± 16.9% vs 5.0 ± 18.9%(p=0.0262)。
  • 他汀治疗组较对照组脾脏FDG摄取变化为-9.8 ± 20.3% vs 11.3 ± 28.8%(p=0.0497)。
  • 他汀治疗组较对照组胸主动脉FDG摄取变化为-19.1 ± 24.2% vs 4.3 ± 15.4%(p=0.003)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: This study aimed to evaluate markers of systemic as well as imaging markers of inflammation in the ascending aorta, bone marrow, and spleen measured by 18F-FDG PET/CT, in HIV+ patients at baseline and following therapy with rosuvastatin. METHODS AND RESULTS: Of the 35 HIV+ patients enrolled, 17 were randomized to treatment with 10 mg/day rosuvastatin and 18 to usual care for 6 months. An HIV- control cohort was selected for baseline comparison of serum inflammatory markers and monocyte markers of inflammation. 18F-FDG-PET/CT imaging of bone marrow, spleen, and thoracic aorta was performed in the HIV+ cohort at baseline and 6 months. While CD14++CD16- and CCR2 expressions were reduced, serum levels of IL-7, IL-8, and MCP-1 were elevated in the HIV+ population compared to the controls. There was a significant drop in FDG uptake in the bone marrow (TBRmax), spleen (SUVmax) and thoracic aortic (TBRmax) in the statin-treated group compared to the control group (bone marrow: - 10.3 ± 16.9% versus 5.0 ± 18.9%, p = .0262; spleen: - 9.8 ± 20.3% versus 11.3 ± 28.8%, p = .0497; thoracic aorta: - 19.1 ± 24.2% versus 4.3 ± 15.4%, p = .003). CONCLUSIONS: HIV+ patients had significantly markers of systemic inflammation including monocyte activation. Treatment with low-dose rosuvastatin in the HIV+ cohort significantly reduced bone marrow, spleen and thoracic aortic FDG uptake.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Boczar KE, Faller E, Zeng W, et al. Anti-inflammatory effect of rosuvastatin in patients with HIV infection: An FDG-PET pilot study. J Nucl Cardiol. 2021. PMID: 34820771. doi:10.1007/s12350-021-02830-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。